SCHEMBL2330397

SCHEMBL2330397

COc1ccc(N2CCN(c3ccc(Cl)cc3)C2=O)cc1N1CCN(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.56
HTR1D P28221 7/20 0.56
HTR1B P28222 7/20 0.56
HTR2A P28223 7/20 0.56
HTR2C P28335 6/20 0.56
HTR1A P08908 6/20 0.56
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
DRD2 P14416 2/20 0.46
DRD3 P35462 2/20 0.46
HTR7 P34969 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325995 0.89 HTR2C (0.55) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL14733344 0.84 POLB (0.47) HTR1AMEN1USP2MAPK1KMT2A
SCHEMBL2329980 0.82 DRD2 (0.45) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL4336114 0.80 HTR3E (0.69) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL2333076 0.79 HRH4 (0.42) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL2325963 0.78 MAPT (0.55) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL2328336 0.77 DRD2 (0.47) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL2329746 0.76 MAPT (0.56) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL4659389 0.75 HTR6 (0.63) HTR6HTR1DHTR1BHTR2AHTR2C
SCHEMBL2327923 0.75 MAPT (0.52) HTR6HTR1DHTR1BHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US claimed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
EP-2536711-A1 5-HT RECEPTOR MODULATORS Cambridge Enterprise Limited (GB) 2012-12-26 EP disclosed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO disclosed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053372-A1 5-HT RECEPTOR MODULATORS HTR1B, HTR5A, HTR1A HTR6 6/4885HTR1D 16/4885HTR1B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.